NYSE - Delayed Quote USD

Artivion, Inc. (AORT)

Compare

29.92

+0.09

(+0.30%)

At close: 4:00:02 PM EST

30.73

+0.81

(+2.71%)

After hours: 6:08:12 PM EST

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.

PR Newswire 2 days ago

AORT
+0.30%
Returns On Capital Are Showing Encouraging Signs At Artivion (NYSE:AORT)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...

Simply Wall St. 11 days ago

AORT
+0.30%
Artivion Third Quarter 2024 Earnings: Beats Expectations

Artivion ( NYSE:AORT ) Third Quarter 2024 Results Key Financial Results Revenue: US$95.8m (up 9.0% from 3Q 2023). Net...

Simply Wall St. last month

AORT
+0.30%
Artivion Reports Third Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2024.

PR Newswire last month

AORT
+0.30%
Artivion to Participate in Upcoming Investor Conferences

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.

PR Newswire last month

AORT
+0.30%
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

PR Newswire last month

AORT
+0.30%
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal.

PR Newswire 2 months ago

AORT
+0.30%
Those who invested in Artivion (NYSE:AORT) a year ago are up 61%

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

Simply Wall St. 2 months ago

AORT
+0.30%
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

Artivion, Inc. ( NYSE:AORT ), is not the largest company out there, but it saw a double-digit share price rise of over...

Simply Wall St. 3 months ago

AORT
+0.30%
A Look At The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Artivion fair value estimate is US$24.82 Artivion's US$24.85...

Simply Wall St. 3 months ago

AORT
+0.30%
Artivion Reports Second Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024.

PR Newswire 4 months ago

AORT
+0.30%
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

PR Newswire 4 months ago

AORT
+0.30%
Artivion Amends Agreements with Endospan

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS"). In 2019, the Company provided a credit facility to Endospan and entered into an option agreement to purchase Endospan upon U.S. Food and Drug Administration ("FDA") approval of NEXUS. The amendme

PR Newswire 5 months ago

AORT
+0.30%
Artivion's (NYSE:AORT) Returns Have Hit A Wall

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Simply Wall St. 5 months ago

AORT
+0.30%
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks 7 months ago

AORT
+0.30%
Shareholders Will Probably Hold Off On Increasing Artivion, Inc.'s (NYSE:AORT) CEO Compensation For The Time Being

Key Insights Artivion will host its Annual General Meeting on 14th of May CEO Pat Mackin's total compensation includes...

Simply Wall St. 7 months ago

AORT
+0.30%
Artivion Reports First Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024.

PR Newswire 7 months ago

AORT
+0.30%
Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting in Toronto, Canada.

PR Newswire 7 months ago

AORT
+0.30%
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

PR Newswire 7 months ago

AORT
+0.30%
Artivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last year

If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost...

Simply Wall St. 7 months ago

AORT
+0.30%

Performance Overview

Return	AORT	S&P 500
YTD	+67.34%	+27.56%
1-Year	+65.58%	+32.14%
3-Year	+62.34%	+29.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Artivion, Inc. (AORT)

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Returns On Capital Are Showing Encouraging Signs At Artivion (NYSE:AORT)

Artivion Third Quarter 2024 Earnings: Beats Expectations

Artivion Reports Third Quarter 2024 Financial Results

Artivion to Participate in Upcoming Investor Conferences

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Those who invested in Artivion (NYSE:AORT) a year ago are up 61%

Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?

A Look At The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Artivion Reports Second Quarter 2024 Financial Results

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

Artivion Amends Agreements with Endospan

Artivion's (NYSE:AORT) Returns Have Hit A Wall

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

Shareholders Will Probably Hold Off On Increasing Artivion, Inc.'s (NYSE:AORT) CEO Compensation For The Time Being

Artivion Reports First Quarter 2024 Financial Results

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

Artivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last year

Performance Overview